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Cyanogen bromide digestion of hemopexin at its 6 methionine residues results in 7 fragments (CBl-CB7) 
partially connected by disultide bridges. By sequence studies of fragments CBl-CB4 and peptides prepared 
by their enzyme cleavage, a continuous amino acid sequence of the N-terminal region of human hemopexin, 
comprising 220 amino acid residues, was determined. The presence of intramolecular disulfide bonds, con- 
necting half-cystine r sidues l26/130 and 165/170, was proved in fragments CB2 and CB3. Fragments CBl- 
CB4 include 5 sites, where hexosamine oligosaccharides are attached (positions 1,41,164, 217 and probably 
223). In the sequenced region two sites sensitive to acid hydrolysis - bonds . ..AspPro... in positions 20/21 
and 187/188 were found. In spite of the fact that pooled material of many donors was studied, no sequence 
heterogeneity was discovered. 
Hemopexin Amino acid sequence Heme transporl 
1. INTRODUCTION 
Hemopexin is a serum &glycoprotein with A4, 
-60000 [l], 20% of which represents the car- 
bohydrate moiety consisting of galactose, man- 
nose, glucosamine and sialic acid [2]. It is a 
transport protein which mediates the transfer of 
heme from methemoglobin to liver parenchymal 
cells and prevents its excretion from the organism. 
The physical and chemical properties of hemopex- 
in and its physiological role have been summarized 
[3,4]. However, there is very little information 
about its covalent structure necessary for deeper 
understanding of its binding function. Only the N- 
terminal amino acid sequence of hemopexin has 
been published [5,6]; some partial sequential data 
have been presented in a recent paper characteriz- 
ing the glycosyl sites and some of the tryptophan 
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sequences [7]. All half-cystine residues are paired 
in disulfide bonds [2]. 
The sequence region determined in this paper 
covers the N-terminal half of the hemopexin 
molecule. 
2. EXPERIMENTAL 
2.1. Materials 
Human hemopexin was isolated as in [8]. Tryp- 
sin (treated with L-1-tosylamido-2-phenylethyl 
chloromethyl ketone) and a-chymotrypsin were 
obtained from Worthington (Freehold, NJ), soy- 
bean trypsin inhibitor and thermolysin from 
Calbiochem (San Diego, CA), Staphylococcus 
aureus V8 proteinase from Miles (UK). Citraconic 
anhydride was from Pierce (Rockford, IL), 4-N,N- 
dimethylaminoazobenzene+isothiocyanate from 
Fluka (Buchs, Switzerland), and the chemicals for 
Edman degradation from Beckman (Berkeley, 
CA). Sephadex@ G-25, G-50 and G-75 were pro- 
ducts of Pharmacia (Uppsala, Sweden), Separon 
SI C-l 8 for preparative high-performance liquid 
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chromatography (HPLC) was supplied by 
Laboratorni piistroje (Prague, Czechoslovakia). 
2.2. Chemical and enzymatic cleavage 
Hemopexin was digested for 20 h at 37°C in 
70% formic acid at a CNBR : protein weight ratio 
of 1:2. Acid hydrolysis was performed under 
similar conditions for 90 h. Enzymatic digestion 
proceeded at pH 8, 37”C, 4 h at a weight ratio of 
1: 50, in case of staphylococcal proteinase the ratio 
was 1: 30, 20-90 h, in the presence of 2 mM 
EDTA. For limited tryptic cleavage citraconylated 
[9] material was used. 
2.3. Isolation and analytical methods 
Cyanogen bromide digest of native hemopexin 
was fractionated on Sephadex G-50 in 0.1 M acetic 
acid. The retarded fraction was rechromato- 
graphed in 1.0 M acetic acid, the material of 
higher M, was S-sulfonated and subjected to 
further separation by reversed phase HPLC with a 
gradient of I-propanol in 0.05% trifluoroacetic 
acid (TFA). The products of acid hydrolysis were 
fractionated on Sephadex G-75 and by HPLC 
under similar conditions. The details concerning 
the isolation and characterization of the fragments 
as well as determination of their order are included 
in another paper (to be published). For smaller 
peptides HPLC with a methanol gradient in 0.05% 
TFA was used. The determination of amino acid 
and amino sugar composition was done in a Dur- 
rum D-500 analyzer. Automated Edman degrada- 
tion by a modified quadrol program [lo] was per- 
formed in a Beckman sequencer 890 C; phenyl- 
thiohydantoins were evaluated by HPLC [ 111. 
Smaller peptides were sequenced by a manual 
technique [ 121. 
3. RESULTS AND DISCUSSION 
By gel filtration of the cyanogen bromide digest 
of hemopexin fragments CB2 and CB3 were ob- 
tained. Each contains two half-cystine residues 
which form intramolecular bridges. After S- 
sulfonation of the remaining material fragments 
CBl and CB4-CB7 were isolated by HPLC. The 
order of the fragments was derived from the deter- 
mination of methionine sequences. The determina- 
tion of the N-terminal sequence of hemopexin is 
presented in fig. 1. 
As observed in [5,6] Edman degradation of 
hemopexin releases an anomalous N-terminal pro- 
duct. With the use of the dansyl-Edman technique 
[13] N-terminal threonine was determined [6]. 
Authors in [7] have found that a galactosamine 
oligosaccharide is linked to this threonine. 
Repeated Edman degradation of hemopexin 
together with peptides from enzymatic hydroly- 
sates enabled us to complete the sequence of frag- 
ment CBl. Residue Asn(41) was found to be the se- 
cond site of glycosidation linking a glucosamine 
oligosaccharide in the usual signal sequence 
CHO 
Asn-X-Ser/Thr [14]. With respect to disulfide 
bonding in CB2 and CB3 the nearest possible part- 
ner to Cys(27) can be Cys(208). Peptide Dl deter- 
mines one of the bonds sensitive to acid cleavage; 
also the N-terminus of peptide T2 results from acid 
cleavage. 
The largest of the fragments in this sequence 
CB2 with a relatively high content of hydrophobic 
residues (especially of tryptophan) is not 
glycosylated. This implies for its localization inside 
the molecule. Limited tryptic digest of CB2 provid- 
ed among others a long fragment LT4 suitable for 
automated Edman degradation which gave a close 
continuation of the N-terminal sequence of the 
fragment. 
The next fragment CB3 contains the second 
acid-sensitive bond. Automatic degradation of 
peptide D2 formed by acid cleavage at this bond 
has made it possible to arrange small peptides in 
the C-terminal section of CB3 and also supplied a 
link to the following fragment CB4. Peptide oxT2 
Fig. 1. N-terminal amino acid sequence of human hemopexin. The peptides are denoted by lines, completely determined 
sequences by full lines, incomplete sequences by broken lines. T, C, Th, V, LT, peptides obtained from trypsin, 
chymotrypsin, thermolysin, staphylococcal proteinase V8 and limited trypsin hydrolysates, respectively; separate 
numbering isused within each cyanogen bromide fragment. CB, D, fragments produced by cyanogen bromide cleavage 
and acid digestion, respectively. Degradation steps in sequencer (-), undefined products of degradation (- - -). CHO, 
glycosylation sites; (+) sites of acid cleavage. 
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P 
CBl 
HO IO 20+ 
Thr-Pro-Leu-Pro-Pro-Thr-Ser-Ala-Hia-Gly-Asn-Val-Ala-Glu-Gly-Glu-Thr-Lys-Pro-Asp-Pro-Asp-Val- 
~--T-r~-r--w--r-r~~r--- --w- - - - -3 
~-------~~-~~-~~~~~_______________~ T, ____________-______-~~-___-_~_-~-_~~~ 
+______--____ c, ________-__-, ~_-_-_-----_-__-_-_- _---- Cl _-- ____--__- -_----- 
c-TZ- 
c_-_-__-__-_---_- ____-_- v, ___ -e-m - -____ ---_I a-2 --_ 
~-_-__--_-_--___-____-_~D~ ______-_--__-_-____-_---__-_-_I~__V3____ 
30 40 CHO 1m 
Thr-Glu-1Zrg-Cys-Ser-Asp-Gly-Trp-Ser-Phe-Asp-Ala-Tkr-Thr-Leu-Asp-Asp-Asn-Gly-Thr-~~et-Leu-Phe- 
3- 
___T1-w-m, ä -------------------- Tj ------_-------_-_-__---_-_-_--- +TT- 
_____ -_-_c2__-- ___- --_-It c3 1+c1- 
-T2+ -c4- 
_;:= ~_vq-_----___ - k__-___7&__ __-__1 I- -Vl-- 
k-_----_ yj-_---_I + LTl-- 
50 60 
Phe-Lys-Gly-Glu-Phe-Val-Trp-Lys-Ser-His-Lys-Trp-Asp-Arg-Glu-Leu-Ile-Ser-Glu-Arg-Trp-Lys-Asn- 
~~~-~~~--~-~rrr---~---r 
-Tl-l t-------T2--------I eT3- -T4- I-T5- 
c11t-----c2-----l /-c!3* +---c4----4c----c5------r -c6- Cc7- 
-_-_V,___--_I I----V2--1 
~---~~~-~--~-~---LT,~----_~-_-_------~---_I-----LT2-------~~~--LT3--- 
70 80 90 
Phe-Pro-Ser-Pro-Val-Asp-Ala-Ala-Phe-Arg-Gln-Gly-His-Asn-Ser-Val-Phe-Leu-I1e-Lys-Gly-Asp-Lys- 
----- 
C7Tg 
I -T6+ 
~---~-~-~C8~--~~~--~,~C9---.--‘ 
-----_--ThJ_-------_I 
~___-- c,o_--___ 
100 110 
Val-Trp-Val-Tyr-Pro-Pro-Glu-Lys-Lys-~uT~y~-~ly-Ty~9Pro-Lys-Leu-Leu-Gln-Asp-Glu-Phe-Pro-Gly- 
,pT7-------4 -- T,O----_--_---- 
--CT94 -c11- c-----c17 
--cio-l I 
_ 
Cl2 -__---a_--_a-_-_--mm 
*-___-__-__--_-___-_ Th2-_~-~~~~~--~~-~-~, ~Vj- 
_--_-----_--_-_--_-_--_~~-~_ LT4 __-----_- ____ -__-__-_-___-___ 
120 I30 
Ile-Pro-Ser-Pro-Leu-Asp-Ala-Ala-Val-Glu-Cys-His-Arg-Gly-Glu-Cys-Gln-Ala-Glu-Gly-Val-Leu-Phe- 
-_---T,O-----_1 
cl3-------rI Cl4 -----_( 
-___--Cl>_- --_Ic ----a------__ - _______ - c,5 ---_- --______ - _____-_- 4 
vj____---__ _--_I b _-____ - __v4_- ___---, +c--__v5----_ 
__________- _____ - _______ -_-__-_-_ LT4 _---______ ____ -____-___-__---- 
140 150 II CB 
PI 
160 
Phe-Gln-Gly-Asp-Arg-Glu-Trp-Phe-Trp-Asp-Leu-Ala-Tkr-Gly-Tkr-Met- ys-Glu-Arg-Ser-Trp-Pro-Ala- 
v-11- C--------Tl2---------~----r-~--r-- 
I-c16- c-C18la Cl9------------l -Tl+ k---oxT2----- 
c____---Ccf7-----_ k--------_C20-_- ---m-_-t ,---_-C,_--______ 
--V5-----4~V6-----_I k__-__-V7-_---_-I t,Thl ______LT4-___-_I 
CHO 170 180 
Val-Gly-Asn-Cys-Ser-Ser-Ala-Leu-Arg-Trp-Leu-Gly-Arg-Tyr-Tyr-Cys-Phe-Gln-Gly-Asn-Gln-Phe-Leu- 
~~~~r~-I-~-~-~--r-~3-Z~~- 
__- -------_-_oxT2---_---- _ + ,----Ip3-- ---) 
____- ____ _c ,___-_-__-__- _I +,3--_-I 
--_--_---_h,------_ 
t 
190 200 III a 
Arg-Phe-Asp Pro-Val-Arg-Gly-Glu-Val-Pro-Pro-Arg-Tyr-Pro-Arg-Asp-Val-Arg-Asp-Tyr-Phe-Met-Pro- 
---3-r------,, - 
e-------T3- -T4------I +T5------I +-6----I +T7- t-T1- 
-c3- bYl- 
)_*Th2-- -d ä ~~~~-~-~---~T~3~--~--------~ 
D2: w---------7---~ --T _ -- - 
210 CHO 220 CHO 230 IV 
Cys-Pro-Gly-Arg-Gly-His-Gly-His-Arg-Asn-Gly-Thr-Gly(His3, 
--t----r--- - --my --c - 
Gly2,Asn,Ser,Thr,Pro)Glu-Tyr-Met.. 
___- Tj__ 1 + _-__ T2_“ ---( r----------_-p--- ---- Tj-_________-__ y 
--a--------- ---__ --__-_-v,____ ____ -__- _____ -_ ____ ---If-V24 _-*---C --...- (D2) 
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was isolated after oxidation of a tryptophan 
positive disulfide-connected peptide, including 
residues 158-170 and 175-185. Asn(104) is the 
third site, where a glucosamine oligosaccharide is 
linked. 
The whole region occupied by fragment CB4 is 
markedly hydrophilic which is characteristic for 
the surface of the molecule. Also, the presence of 
two glycosylation sites places this sequence region 
at the surface of hemopexin. The Edman degrada- 
tion of the fragment seems to be negatively af- 
fected by the glycosylation sites. Also the high con- 
tent of the histidine and glycine residues com- 
plicates the interpretation of results. Positions 
221-229 remain sequentially undetermined. The 
alignment of the partial sequence characterizing 
glycosylation sites III and IV by authors in [7] with 
positions 213-228 of our sequence would make it 
possible to formulate the C-terminus of the struc- 
ture as 
220 CHO 
. .Gly-Thr-Gly-His-Gly-Asn Ser-Thr-His-His- 
230 
Gly-ProGlu-Tyr-Met. 
The sequence of the remaining C-terminal part 
of hemopexin is also under investigation. 
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